ALPHAMAB ONCOLOGY

Insiders Alphamab Oncology

Equities

9966

KYG0330A1013

Market Closed - Hong Kong S.E. Other stock markets 09:08:34 21/06/2024 BST			5-day change	1st Jan Change
2.58 ^HKD	-2.27%		-3.37%	-61.14%

06-05	ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment	MT
06-05	Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates	MT

Insiders

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Alphamab Oncology Resignation of Xu Zhan Kevin as Non-Executive Director and Member of the Strategy Committee	30/06/23	CI
HBM Holdings Names CFO/Chief Business Officer	14/11/22	MT
Alphamab Oncology Announces Board and Committee Changes	16/06/22	CI
Alphamab Oncology Hires Former Junshi Bio Marketing Head as Commercial Chief; Shares Jump 3%	02/11/21	MT
Alphamab Oncology Announces Appointment of HAN Jing as Chief Commercial Officer	01/11/21	CI
Alphamab Oncology Announces Board Changes	27/08/21	CI
Alphamab Oncology : CASI Pharmaceuticals Chief Financial Officer Moves to Alphamab Oncology	31/03/21	MT
Alphamab Oncology Appoints Johannes Nippgen as its Chief Medical Officer	30/03/21	CI
Alphamab Oncology Appoints Xu Weihao as Chief Financial Officer	30/03/21	CI
Alphamab Oncology Announces Executive Changes	07/12/20	CI
Alphamab Oncology Announces Management Changes	20/07/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Protect and grow your investments with the help of our experts

Securing my Investments

fermer